子宫内膜癌分子分型:指导生育力保存的有前景策略
本研究纳入2010年1月1日至2021年6月30日接受孕激素治疗的20例≤48岁绝经前子宫内膜癌或非典型子宫内膜增生患者,按分子分型比较孕激素反应。拷贝数低型肿瘤完全缓解率最高,微卫星不稳定高型最差;完全缓解后复发常见。结论认为分子分型可能与孕激素反应相关,需更大规模研究。
要点
- 拷贝数低型肿瘤孕激素完全缓解率为62%,微卫星不稳定高型无完全缓解且进展多见。
- 10例完全缓解患者中4例(40%)复发,完全缓解至复发中位时间16个月。
- 作者认为完全缓解后复发常见,密切监测是必要的。
核心结论
- 分子分型可能与子宫内膜癌或非典型子宫内膜增生患者的孕激素反应相关。
- 拷贝数低型肿瘤反应最佳,微卫星不稳定高型反应最差。
- 完全缓解后复发常见,密切监测是必要的。
研究设计与样本
- 研究纳入2010年1月1日至2021年6月30日接受孕激素治疗的绝经前、年龄≤48岁、且有肿瘤-正常测序数据的子宫内膜癌或非典型子宫内膜增生患者。
- 肿瘤按分子分型分为POLE超突变型、微卫星不稳定高(MSI-H)型、拷贝数高(CN-H)型或拷贝数低(CN-L)型。
- 共纳入20例患者,其中7例(35%)为非典型子宫内膜增生,13例(65%)为子宫内膜癌。
主要发现
- 20例中16例(80%)为拷贝数低型,3例(15%)为微卫星不稳定高型,1例(5%)为POLE超突变型。
- 孕激素治疗中位时间为22个月(范围3-115),10例(50%)达到完全缓解,完全缓解中位时间为9个月(范围3-32)。
- 4例(20%)为疾病稳定,6例(30%)为疾病进展。
- 拷贝数低型中10例(62%)完全缓解、3例(19%)疾病稳定、3例(19%)疾病进展;微卫星不稳定高型中1例(33%)疾病稳定、2例(66%)疾病进展;POLE超突变型1例疾病进展。
- 中位随访48个月(范围12-123),10例完全缓解患者中4例(40%)复发,完全缓解至复发中位时间16个月(范围5-102)。
临床怎么用
- 作者认为分子分型可能有助于指导子宫内膜癌或非典型子宫内膜增生患者的孕激素治疗决策。
- 作者认为完全缓解后复发常见,密切监测是必要的。
- 作者指出需要更大规模研究探讨分子分型在子宫内膜癌或非典型子宫内膜增生药物治疗中的作用。
局限性
- 作者指出需要更大规模研究探讨分子分型在子宫内膜癌或非典型子宫内膜增生药物治疗中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the association of molecular subtype with progesterone response in patients with endometrial cancer (EC) or atypical endometrial hyperplasia (AEH). METHODS: Premenopausal patients aged ≤48 years with tumor-normal sequencing data who received progesterone for EC/AEH from 1/1/2010-6/30/2021 were identified. Tumors were classified as POLE-ultramutated, microsatellite instability-high (MSI-H), copy number-high (CN-H), or copy number-low (CN-L) molecular subtype. Best response to progesterone was compared by subtype. Appropriate statistical tests were performed. RESULTS: Of 20 patients, 7 (35%) had AEH and 13 (65%) had EC. Sixteen tumors (80%) were CN-L, 3 (15%) were MSI-H, and 1 (5%) was POLE-ultramutated. Median time on progesterone was 22 months (range, 3-115). Ten patients (50%) had complete response (CR); median time to CR was 9 months (range, 3-32). Four patients (20%) had stable disease (SD) and 6 (30%) had progressive disease (PD). For CN-L tumors, 10 patients (62%) had CR, 3 (19%) had SD, and 3 (19%) had PD. For MSI-H tumors, 1 patient (33%) had SD and 2 (66%) had PD. For POLE-ultramutated tumors, 1 patient had PD. Median follow-up was 48 months (range, 12-123). Four of 10 patients (40%) with CR recurred; median time from CR to recurrence was 16 months (range, 5-102). CONCLUSION: Molecular subtype may be associated with progesterone response in patients with EC/AEH. CN-L tumors had the best response, and MSI-H tumors had the poorest. Recurrence after CR is common, and close surveillance is warranted. Larger studies investigating the role of molecular classification in medical management of EC/AEH are needed.
引用
- Dagher C, Manning-Geist B, Ellenson LH, et al. Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation. Gynecol Oncol. 2023. PMID: 37992549. doi:10.1016/j.ygyno.2023.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。